Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Celcuity is a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies.

Longhua Hospital Shanghai University of TCM, a subsidiary of Shanghai University of Traditional Chinese Medicine, is a company headquartered in Shanghai, China. The firm provides hospital services.

Shangqiu Cancer Institute, established on 1997-08-01, Business scope includes biotechnology development.Development of new drugs for preventing and treating tumors.to promote.application.Production.Sales.***

Ketu (Gu'an) Biotechnology Co., Ltd., established on 2022-02-28, Business scope includes technology development in the field of biotechnology,technical consulting,Technical Services;Technical testing;Breeding and selling laboratory mice;Sales of chemical reagents;Import and export,Technology Import and Export,Agent import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)*

Beijing Justeng Medical Laboratory Co., Ltd., established on 2022-07-26, Business scope includes licensed projects:medical service;Drug Clinical Trial Services;Inspection and testing service;Class III medical device business;Class III Medical Device Leasing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Information Technology Consulting Services;Health Consulting Services(Does not include medical services);Development of Human Gene Diagnosis and Therapy Technology;Human stem cell technology development and application;R&D and application of cell technology;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Class I Medical Device Leasing;Class II Medical Device Leasing.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Nanjing Licheng Biomedical Technology Co., Ltd., established on 2018-10-17, Business scope includes drug research and development;Biotechnology Extension Services;software development;design,acting,Publish various domestic advertisements;graphic design;Intellectual Property Agency Services;cosmetic,crafts,Jewelry,Computer hardware and software and auxiliary equipment,Daily necessities,Wholesale of clothing, shoes and hats,Purchasing agency sales and Internet sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Health food production;Health food sales;food production;food business;food business(Selling prepackaged food);food business(sell bulk food);Food additive production;Import and export;Technology Import and Export;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of biopesticide technology;Food Additive Sales;Cosmetics Wholesale;Cosmetics Retail(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Zhejiang Ketu Medical Technology Co., Ltd., established on 2018-01-15, Business scope includes medical inspection technology,Pharmacy,Technology development for medical research;Technology Development of Gene Sequencing for Drug Evaluation,technical consulting,Technical Services;medical instruments,In vitro diagnostic reagents,biological reagent(Removal of hazardous chemicals and precursor chemicals),Technical development of machinery and equipment;Development of new anticancer drugs;Drug Preclinical Development;Drug Clinical Development;Biomarker R&D;Technical services in the field of biotechnology,technical consulting,Technical testing,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)